大洋集團(01991.HK)全矽膠口罩完成美國FDA產品登記
格隆匯3月19日丨大洋集團(01991.HK)公佈,於2020年3月18日,公司全資擁有附屬公司,東莞太洋橡塑製品有限公司,於美國食品和藥物管理局(FDA)完成機構註冊;其自主研發的自吸過濾式防顆粒物呼吸器(Non-powered Air-purifying Particle Respirator,簡稱全矽膠口罩)亦同時完成FDA產品登記。
此次完成FDA機構註冊及產品登記,標誌着集團的全矽膠口罩可以進入美國市場進行銷售,對進一步提升集團產品競爭力和促進海外市場業務的發展具有重要的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.